https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%B8%95%E8%AF%BA%E5%AE%BE%E5%8F%B8%E4%BB%96
帕诺宾司他 - 版本历史
2026-04-18T22:36:22Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%B8%95%E8%AF%BA%E5%AE%BE%E5%8F%B8%E4%BB%96&diff=314718&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T07:41:24Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[帕诺宾司他]]</strong>（<strong>[[Panobinostat]]</strong>，商品名：<strong>[[Farydak]]</strong>）是一种高效、口服的广谱<strong>[[组蛋白去乙酰化酶]]</strong>（<strong>[[HDAC]]</strong>）抑制剂，属于氧肟酸衍生物。作为一种强效的表观遗传调节药物，它能同时靶向I、II及IV型[[HDAC]]同工酶。通过抑制[[HDAC]]活性，[[帕诺宾司他]]诱导细胞内[[组蛋白]]及非组蛋白（如[[p53]]、[[HSP90]]、[[$\alpha$-tubulin]]）的高度乙酰化，进而导致染色质重塑、细胞周期停滞并诱导<strong>[[凋亡]]</strong>。在2026年的临床体系中，该药主要联合[[硼替佐米]]和[[地塞米松]]，用于治疗复发或难治性<strong>[[多发性骨髓瘤]]</strong>（[[RRMM]]），是表观遗传治疗药物在血液恶性肿瘤领域的代表性分子。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[帕诺宾司他]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Panobinostat]] / [[Farydak]] · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[HDAC1]]/[[2]]/[[3]]/[[6]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[CAS]]登记号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">404950-80-7</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[广谱HDAC抑制剂]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3065 / 3066 / 8841</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子式</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">$C_{21}H_{23}N_{3}O_{2}$</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">349.43 Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发公司</th><br />
<td style="padding: 12px; color: #0f172a;">[[诺华]] / [[SecuraBio]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多靶点表观重塑</h2><br />
<br />
<br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[帕诺宾司他]]的作用机制通过纠正肿瘤细胞内异常的乙酰化水平来发挥抗癌活性：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>染色质重塑：</strong>通过抑制[[HDAC1]]、[[HDAC2]]和[[HDAC3]]，[[帕诺宾司他]]增加组蛋白末端[[赖氨酸]]残基的乙酰化，使致密的染色质结构变得松散（[[常染色质]]化），从而重新激活被沉默的抑癌基因。</li><br />
<li style="margin-bottom: 12px;"><strong>干扰HSP90伴侣功能：</strong>抑制[[HDAC6]]可诱导<strong>[[HSP90]]</strong>高度乙酰化，削弱其对致癌客户蛋白（如[[BCR-ABL]]、[[FLT3]]、[[Akt]]）的稳定作用，加速这些癌蛋白的泛素化降解。</li><br />
<li style="margin-bottom: 12px;"><strong>蛋白质组应激：</strong>在骨髓瘤细胞中，[[帕诺宾司他]]与[[蛋白酶体抑制剂]]（如[[硼替佐米]]）产生强协同作用。通过抑制[[HDAC6]]介导的[[聚集体]]（[[Aggresome]]）途径，导致错误折叠蛋白蓄积，诱发致命的[[内质网应激]]。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：Farydak 联合疗法</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症场景</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">联合方案</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">核心临床数据 (Panorama 1)</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[复发难治骨髓瘤]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">+ [[硼替佐米]] + [[地塞米松]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">相比标准方案，显著延长中位 [[PFS]]（12个月 vs 8个月）。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[既往二线治疗失败]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">三联方案</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对经[[来那度胺]]治疗后的亚群表现出更显著的获益优势。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">安全性考量</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">(黑框警告内容)</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; color: #e11d48;">需严格监控严重[[腹泻]]及致命性[[心律失常]]（[[QT间期延长]]）。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：风险管理与个体化剂量</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
2026年精准医疗共识强调了[[帕诺宾司他]]应用中的“效毒平衡”策略：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>序贯给药优化：</strong>推荐采用间歇给药方案（如每周三次，每三周停一周），以缓解胃肠道毒性。</li><br />
<li style="margin-bottom: 12px;"><strong>心脏安全性筛查：</strong>治疗前必须评估 [[ECG]] 及血清电解质（尤其是[[钾]]、[[镁]]）。对于 [[QTc]] > 450ms 的患者应避免使用。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药逆转策略：</strong>当患者对[[蛋白酶体抑制剂]]产生获得性耐药时，加入[[帕诺宾司他]]可显著提高肿瘤细胞对[[硼替佐米]]的二次敏感度。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[HDAC]]：</strong>负责去除乙酰基，使组蛋白与 DNA 结合紧密，抑制基因转录。</li><br />
<li style="margin-bottom: 8px;"><strong>[[表观遗传学]]治疗：</strong>不改变 DNA 序列，通过调节基因表达水平来对抗肿瘤。</li><br />
<li style="margin-bottom: 8px;"><strong>[[伏立诺他]] (Vorinostat)：</strong>首个获批的 HDAC 抑制剂，但帕诺宾司他的效价（[[IC50]]）通常更高。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HSP90]]：</strong>一种分子伴侣，其功能受乙酰化状态严格调控。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>San-Miguel JF, et al. (2014).</strong> <em>Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 1).</em> <strong>[[The Lancet Oncology]]</strong>. 15(11):1195-206.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该项关键 III 期研究奠定了帕诺宾司他在骨髓瘤三联方案中的核心地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Laubach JP, et al. (2015).</strong> <em>Panobinostat for the treatment of multiple myeloma.</em> <strong>[[Expert Opinion on Investigational Drugs]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：系统阐述了 HDAC 抑制剂在协同蛋白酶体通路中的分子药理逻辑。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[帕诺宾司他]] (Panobinostat) 药效生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[HDAC1]]•[[HDAC6]]•[[HSP90]]•[[p53]]•[[p21]]•[[Aggresome]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">联合/迭代</td><br />
<td style="padding: 10px 15px; color: #334155;">[[硼替佐米]]•[[卡非佐米]]•[[达雷妥尤单抗]]•[[西达本胺]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Novartis]]•[[SecuraBio]]•[[FDA]]•[[NCCN]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克服蛋白酶体抑制剂耐药]]•[[针对三阴性乳腺癌的联合探索]]•[[选择性HDAC6抑制剂研发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164